Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis

Elliott, Suzanne L., Suhrbier, Andreas, Miles, John J., Lawrence, Greg, Pye, Stephanie J., Le, Thuy T., Rosenstengel, Andrew, Nguyen, Tam, Allworth, Anthony, Burrows, Scott R., Cox , John, Pye, David, Moss, Denis J. and Bharadwaj, Mandvi (2008) Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis. Journal of Virology, 82 3: 1448-1457. doi:10.1128/JVI.01409-07

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ172602_OA.pdf Full text (open access) application/pdf 340.46KB 0

Author Elliott, Suzanne L.
Suhrbier, Andreas
Miles, John J.
Lawrence, Greg
Pye, Stephanie J.
Le, Thuy T.
Rosenstengel, Andrew
Nguyen, Tam
Allworth, Anthony
Burrows, Scott R.
Cox , John
Pye, David
Moss, Denis J.
Bharadwaj, Mandvi
Title Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis
Journal name Journal of Virology   Check publisher's open access policy
ISSN 0022-538X
1070-6321
1098-5514
Publication date 2008-02-01
Year available 2008
Sub-type Article (original research)
DOI 10.1128/JVI.01409-07
Open Access Status File (Publisher version)
Volume 82
Issue 3
Start page 1448
End page 1457
Total pages 10
Place of publication Washington, DC, United States
Publisher American Society of Microbiology
Collection year 2009
Language eng
Formatted abstract
A single blind, randomized, placebo-controlled, single-center phase I clinical trial of a CD8+ T-cell peptide epitope vaccine against infectious mononucleosis was conducted with 14 HLA B*0801-positive, Epstein-Barr virus (EBV)-seronegative adults. The vaccine comprised the HLA B*0801-restricted peptide epitope FLRGRAYGL and tetanus toxoid formulated in a water-in-oil adjuvant, Montanide ISA 720. FLRGRAYGL-specific responses were detected in 8/9 peptide-vaccine recipients and 0/4 placebo vaccine recipients by gamma interferon enzyme-linked immunospot assay and/or limiting-dilution analysis. The same T-cell receptor Vβ CDR3 sequence that is found in FLRGRAYGL-specific T cells from most EBV-seropositive individuals could also be detected in the peripheral blood of vaccine recipients. The vaccine was well tolerated, with the main side effect being mild to moderate injection site reactions. After a 2- to 12-year follow-up, 1/2 placebo vaccinees who acquired EBV developed infectious mononucleosis, whereas 4/4 vaccinees who acquired EBV after completing peptide vaccination seroconverted asymptomatically. Single-epitope vaccination did not predispose individuals to disease, nor did it significantly influence development of a normal repertoire of EBV-specific CD8+ T-cell responses following seroconversion.
Q-Index Code C1
Q-Index Status Confirmed Code

Document type: Journal Article
Sub-type: Article (original research)
Collections: 2009 Higher Education Research Data Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 42 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 54 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Mon, 30 Mar 2009, 14:45:25 EST by Geraldine Fitzgerald on behalf of Faculty Of Health Sciences